Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FVIIa as used pharmacologically is not TF dependent in hemophilia B mice

15 Jan 2014

Abstract excerpt

Activated factor VII is approved for treating hemophilia patients with autoantibodies to their factor IX or FVIII; however, its mechanism of action remains controversial. Some studies suggest that FVIIa requires tissue factor (TF) for function and that the reason for the high dose requirement is that it must compete with endogenous FVII for tissue factor. Others suggest that FVIIa binds platelets where it...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Coagulation and Thrombosis Mechanisms
Share to Hemophilia Treatment and Research
Share to Platelet Disorders and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24425804
DOI: 10.1182/blood-2013-08-522987

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FVIIa as used pharmacologically is not TF dependent in hemophilia B micePMID 24425804Read ↗

Pharmacological concentrations of recombinant factor VIIa restore hemostasis independent of tissue factor in antibody-induced hemophilia mice.Semantic proximity Read ↗

Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice.Semantic proximity Read ↗

Creation of a mouse expressing defective human factor IX.Semantic proximity Read ↗

Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant.Semantic proximity Read ↗

Platelet gene therapy by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces humoral immune tolerance in FIX(null) mice.Semantic proximity Read ↗

FIX-Triple, a gain-of-function factor IX variant, improves haemostasis in mouse models without increased risk of thrombosis.Semantic proximity Read ↗

Phenotypic correction of hemophilia A by ectopic expression of activated factor VII in platelets.Semantic proximity Read ↗

Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice.Semantic proximity Read ↗

Catalytic domain modification and viral gene delivery of activated factor VII confers hemostasis at reduced expression levels and vector doses in vivo.Semantic proximity Read ↗

Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV.Semantic proximity Read ↗

The Function of extravascular coagulation factor IX in haemostasisSemantic proximity Read ↗

The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.